Ten-Year Relative Survival for Epithelial Ovarian Cancer

Baldwin, Lauren; Huang, Bin; Miller, Rachel W.; Tucker, T. C.; Goodrich, S.; Podzielinski, Iwona; DeSimone, Christopher P.; Ueland, F.; Nagell, J.R. van; Seamon, Leigh G.

doi:10.1097/aog.0b013e318264f794

Cited by 273 publications

(204 citation statements)

References 26 publications

Supporting

Mentioning

184

Contrasting

Unclassified

Order By: Relevance

“…Currently, the leading first line treatment includes surgery to debulk the tumour and multiple cycles of carboplatin and paclitaxel chemotherapy [3,4]. Despite initial positive responses to therapy in approximately 75% of patients five year survival rates are still under 30% [5][6][7]. Therefore, novel therapeutic approaches are urgently needed.…”

Section: Introductionmentioning

confidence: 99%

Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine

Xiang¹,

Gao²,

Wilson³

et al. 2015

Vaccine

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine

Xiang¹,

Gao²,

Wilson³

et al. 2015

Vaccine

View full text Add to dashboard Cite

“…Despite the use of modern therapeutic approaches, patients suffering from ovarian cancer still have poor prognosis, with a 5-year survival rate lower than 30% [2]. The high mortality of ovarian cancer is mainly due to the difficulty in early diagnosis, metastasis, and resistance to chemotherapeutics [3].…”

Section: Introductionmentioning

confidence: 99%

A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells

Han¹,

Zhen²,

Ye³

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background: Many microRNAs (miRs) are dysregulated in cancers, and aberrant miR expression patterns have been suggested to correlate with chemo-resistance of cancer cells. We aim to study the role of miR-30 family members in cisplatin-resistance of ovarian cancer cells. Methods: qRT-PCR was used to compare differential expression levels of miR-30 family members in ovarian cancer cell line A2780 and its cisplatin-resistant derivative CP70. Changes of cisplatin-sensitivity in miR-30a-5p- and miR-30c-5p-overexpressed-CP70 cells and miR-30a-5p- and miR-30c-5p-inhibited-A2780 cells were examined by CCK8 assay and apoptosis analysis using flow cytometry; targets of miR-30a/c-5p were analyzed by western blotting and luciferase reporter assay; methylation regulation of pre-miR-30a/c-5p was examined by methylation specific PCR. Results: miR-30a-5p and miR-30c-5p, in contrast to other miR-30 family members, dramatically decreased in cisplatin-resistant CP70 cells due to overexpressed-DNMT1 induced aberrant methylation. miR-30a/c-5p in turn directly inhibited DNMT1 as well as Snail. Forced expression of miR-30a/c-5p or knocking down of DNMT1 and Snail promoted cisplatin susceptibility and partially reversed epithelial-mesenchymal transition (EMT) in CP70 cells, while inhibition of miR-30a/c-5p or ectopic expression of DNMT1 and Snail induced cisplatin resistance and partial EMT in cisplatin-sensitive A2780 cells. Conclusions: A feedback loop between miR-30a/c-5p and DNMT1 is a potent signature for cisplatin-resistance and EMT in ovarian cancer, promising a potential target for improved anti-cancer treatment.

show abstract

“…Epithelial ovarian cancer (EOC) accounts for nearly 90% of all ovarian malignant diseases and serves as a strong and long-standing interest in OC research. For patients in early stage (stage I), the tumor is confined to ovaries only, which is highly curable with an expected 5-year survival rate at about 89% [2]. However, due to the absence of specific symptoms and the lack of effective screening strategies, approximately 75% of OC patients present at an advanced stage disease accompanied with metastasis within the peritoneal cavity, and the overall survival (OS) rates are only 17-36% [2].…”

Section: Introductionmentioning

confidence: 98%

“…For patients in early stage (stage I), the tumor is confined to ovaries only, which is highly curable with an expected 5-year survival rate at about 89% [2]. However, due to the absence of specific symptoms and the lack of effective screening strategies, approximately 75% of OC patients present at an advanced stage disease accompanied with metastasis within the peritoneal cavity, and the overall survival (OS) rates are only 17-36% [2]. In addition to the difficulty in early diagnosis, chemoresistance is the main challenge for the poor survival rates of OC patients.…”

Section: Introductionmentioning

confidence: 99%

Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy

Deng

Wang

et al. 2016

Expert Review of Proteomics

View full text Add to dashboard Cite

We review the medical literature, discuss MS-based technologies with respect to chemoresistant ovarian cancer and summarize the promising chemoresistant biomarkers identified. In addition, the challenges and future perspectives of biomarker discovery research are explored. With the employment of mass spectrometry-based (MS-based) proteomics, biomarker discovery of ovarian cancer has made great progress in the last decade. Many potential biomarkers were identified by MS-based proteomics technologies, some of which have been validated for further extensive studies in clinical settings. Expert commentary: The discovery of chemoresistant biomarkers is a newly developing area and may provide a clue for predicting chemotherapeutic response and discover therapeutic targets for paving the way of personalized medicine. Multiple complementary MS-based proteomics approaches hold promise for finding novel therapeutic targets in ovarian cancer treatment.

show abstract

Ten-Year Relative Survival for Epithelial Ovarian Cancer

Abstract: The 10-year relative survival for stage III is higher than expected. This information provides the physician and the patient with more accurate prognostic information.

Cited by 273 publications

References 26 publications

Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine

Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine

A Feedback Loop Between miR-30a/c-5p and DNMT1 Mediates Cisplatin Resistance in Ovarian Cancer Cells

Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy

Contact Info

Product

Resources

About